drugset / Trial / NCT04030195
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r CLL/SLL.
Timeline
- Start
- 2020-03-24
- Primary completion
- 2021-06-24
- Completion
- 2021-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PBCAR20A | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | PBCAR20A | Cell therapy | 2.4e+08 cells | Intravenous |
| Subject | PBCAR20A | Cell therapy | 4.8e+08 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |